INT89462

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2000
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 3.94
Pain Relevance 0.36

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (PLAG1) intracellular (PLAG1) DNA binding (PLAG1)
Anatomy Link Frequency
lymph node 1
arm 1
PLAG1 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 1 99.20 Very High Very High Very High
headache 1 91.36 High High
Analgesic 4 82.52 Quite High
palliative 7 80.56 Quite High
imagery 1 39.76 Quite Low
Pain 18 36.08 Quite Low
Spinal cord 2 11.20 Low Low
Pain management 2 5.00 Very Low Very Low Very Low
Neuropathic pain 1 5.00 Very Low Very Low Very Low
anesthesia 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Metastasis 35 98.76 Very High Very High Very High
Prostate Cancer 10 98.58 Very High Very High Very High
Disease 5 93.16 High High
Reprotox - General 1 17 91.64 High High
Headache 1 91.36 High High
Dysphagia 1 90.56 High High
Syndrome 4 90.48 High High
Dysarthria 1 89.44 High High
Osteoporosis 3 86.16 High High
Cancer 16 84.24 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A fifty-five years old man presenting multiple lymph node and bone metastases of prostate carcinoma was treated with LH-RH agonist and Flutamide, which induced transient decrease in serum PSA levels and size of lymph node metastases.
Negative_regulation (decrease) of PSA in lymph node associated with agonist, prostate cancer and metastasis
1) Confidence 0.57 Published 2000 Journal Nippon Hinyokika Gakkai Zasshi Section Abstract Doc Link 10897582 Disease Relevance 1.59 Pain Relevance 0.14
A partial response, based on a > 50% decrease in the prostate specific antigen (PSA) level, was achieved in 27 patients (54%; 95% confidence interval [95% CI], 44.7-65.0%), 16 of whom (32%; 95%CI, 23.9-43.2%) had a > 75% decrease in their PSA levels.
Negative_regulation (decrease) of PSA
2) Confidence 0.57 Published 2001 Journal Cancer Section Body Doc Link 11745301 Disease Relevance 0.14 Pain Relevance 0
A post-treatment reduction in the level of prostate specific antigen (PSA) by 50% has been shown to correlate with survival and has been accepted by consensus as a valid endpoint in clinical trials.
Negative_regulation (reduction) of PSA
3) Confidence 0.57 Published 2003 Journal Cancer Treat. Rev. Section Abstract Doc Link 12787712 Disease Relevance 0.60 Pain Relevance 0.08
A >50% decrease in prostrate specific antigen (PSA) was seen in 9/27 (33.3%) in the satraplatin plus prednisone arm vs. 2/23 (8.7%) on the prednisone alone arm.
Negative_regulation (decrease) of PSA in arm
4) Confidence 0.57 Published 2005 Journal Oncology Section Abstract Doc Link 15741753 Disease Relevance 0.57 Pain Relevance 0.08
RESULTS: A decline in the prostate specific antigen (PSA) level was observed in 5 patients (27%) with a 0-25% decline in 2 patients and a >50% decline in 3 patients (16%, 95% confidence interval 3.4-39.6).
Negative_regulation (decline) of PSA
5) Confidence 0.57 Published 2006 Journal Anticancer Res. Section Body Doc Link 16739316 Disease Relevance 0.08 Pain Relevance 0
A partial response, based on a > 50% decrease in the prostate specific antigen (PSA) level, was achieved in 27 patients (54%; 95% confidence interval [95% CI], 44.7-65.0%), 16 of whom (32%; 95%CI, 23.9-43.2%) had a > 75% decrease in their PSA levels.
Negative_regulation (decrease) of PSA
6) Confidence 0.42 Published 2001 Journal Cancer Section Body Doc Link 11745301 Disease Relevance 0.12 Pain Relevance 0
In the setting of castrate serum testosterone levels, resistance is often indicated by a rising level of prostate-specific antigen (psa) before symptoms progress.
Negative_regulation (level) of psa
7) Confidence 0.41 Published 2007 Journal Current Oncology Section Body Doc Link PMC1891195 Disease Relevance 0.84 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox